Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Aclaris Therapeutics reported positive Phase 1b proof-of-concept primary analysis results for ATI-052, its anti-TSLP/IL-4Rα bispecific being studied in atopic dermatitis. The headline provides no numerical efficacy or safety results, so the magnitude of the clinical benefit cannot be assessed.